Procter & Gamble Health Limited
NSE: PGHL BSE: PGHL
NSE
5,223.50
5.50 (0.11%)
Prev Close
5218
Open Price
5224.5
Volume
3,571
Today Low / High
5178 / 5253
52 WK Low / High
4636.55 / 5850
Range
4,962 - 5,485
BSE
5,236.20
6.95 (0.13%)
Prev Close
5229.25
Open Price
5200.05
Volume
289
Today Low / High
5180.5 / 5246.1
52 WK Low / High
4640.3 / 5835.95
Range
4,974 - 5,498
The stock is currently trading on both the National Stock Exchange (NSE) and Bombay Stock Exchange (BSE). On the NSE, the stock is priced at 5223.5 (target range: 4,962 - 5,485), reflecting a change of 5.5 (0.1054%). On the BSE, it is listed at 5236.2 (target range: 4,974 - 5,498), showing a change of 6.95 (0.13291%). Both the NSE and BSE data indicate positive movement, suggesting the stock is on an upward trend. This could be an attractive opportunity for investors looking for growth.
21 Apr
5,224.50
-0.02%
17 Apr
5,183.00
0.68%
16 Apr
5,230.00
-0.58%
15 Apr
5,179.50
0.98%
11 Apr
5,239.80
-1.38%
09 Apr
5,115.00
2.08%
08 Apr
5,160.00
-0.90%
07 Apr
5,061.40
1.71%
04 Apr
5,300.20
-1.47%
03 Apr
5,260.00
0.78%
02 Apr
5,151.05
2.05%
01 Apr
5,146.50
0.16%
28 Mar
5,002.60
2.88%
27 Mar
5,359.30
-6.66%
26 Mar
5,422.75
-2.05%
25 Mar
5,461.50
-0.71%
24 Mar
5,506.05
-0.81%
Procter & Gamble Health Limited Graph
Procter & Gamble Health Limited Price Target Predictions: Bullish vs. Bearish Scenarios with Ranges
If you are looking for the target price for Procter & Gamble Health Limited T1, T2, T3 for both Bullish and Bearish scenarios, here it is. For Bullish: T1, T2, T3. For Bearish: T1, T2, T3. The stock current price is 5,223.50, with potential price targets ranging from T1, T2, and T3 in both directions based on market conditions.
| Scenario | Price | Target | Range |
|---|---|---|---|
| Bullish Scenario | 5,236.20 | 5,288.56 | 4,759.71 - 5,817.42 |
| 5,340.92 | 4,272.74 - 6,409.11 | ||
| 5,393.29 | 3,775.30 - 7,011.27 | ||
| Bearish Scenario | 5,236.20 | 5,183.84 | 4,665.45 - 5,702.22 |
| 5,131.48 | 4,105.18 - 6,157.77 | ||
| 5,079.11 | 3,555.38 - 6,602.85 |
Overview of Procter & Gamble Health Limited
ISIN
INE199A01012
Industry
Drug Manufacturers - Specialty & Generic
Vol.Avg
8,963
Market Cap
86,706,866,654
Last Dividend
160
Official Website
IPO Date
2002-07-01
DCF Diff
-2,213.73
DCF
7,439
Financial Ratios Every Investor Needs
Stock Dividend of PGHL
| Date | Label | Adj Dividend | Dividend | Record Date | Payment Date | Declaration Date |
|---|---|---|---|---|---|---|
| 2025-02-21 | February 21, 25 | 80 | 80 | 2025-02-21 | 2025-03-07 | |
| 2024-11-28 | November 28, 24 | 60 | 60 | 2024-11-28 | 2024-12-25 | |
| 2024-02-14 | February 14, 24 | 200 | 200 | 2024-02-14 | 2024-03-03 | |
| 2023-11-23 | November 23, 23 | 50 | 50 | 2023-11-23 | 2023-12-30 | |
| 2023-02-13 | February 13, 23 | 45 | 45 | 2023-02-13 | 2023-03-05 |
Annual Financial Income Report
| Date | Revenue | Co.Rev | GP | GPR | R&D Expenses | G&A Expenses | Operating Income | Net Income | EPS | EBITDA | NIR |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2024-06-30 | 1,151.26 Cr | 330.56 Cr | 820.70 Cr | 0.7129 | 0.00 Cr | 0.00 Cr | 606.98 Cr | 200.98 Cr | 121.07 | 307.44 Cr | 0.1746 |
| 2023-06-30 | 1,229.62 Cr | 361.84 Cr | 867.78 Cr | 0.7057 | 5.71 Cr | 148.17 Cr | 314.24 Cr | 229.47 Cr | 138.24 | 342.72 Cr | 0.1866 |
| 2022-06-30 | 1,092.04 Cr | 367.11 Cr | 724.93 Cr | 0.6638 | 6.55 Cr | 23.32 Cr | 260.31 Cr | 192.52 Cr | 115.98 | 280.52 Cr | 0.1763 |
| 2021-06-30 | 990.79 Cr | 339.27 Cr | 651.52 Cr | 0.6576 | 3.93 Cr | 47.43 Cr | 234.98 Cr | 176.80 Cr | 106.51 | 263.77 Cr | 0.1784 |
| 2020-06-30 | 903.38 Cr | 501.63 Cr | 401.76 Cr | 0.4447 | 5.73 Cr | 72.83 Cr | 196.84 Cr | 169.39 Cr | 102.04 | 208.80 Cr | 0.1875 |
Annual Financials Balance Sheet
| Date | C&C Equ. | Tot. Assets | Tot. Liab. | Stock. Equity | Tot. Debt | Net Debt | Inv. | PP&E (Net) | Curr. Def. Rev. | Non-Curr. Def. Rev. | LT Invest. | Curr. Liab. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2024-06-30 | 244.36 Cr | 794.36 Cr | 256.12 Cr | 538.2400 Cr | 9.56 Cr | -234.80 Cr | 109.11 Cr | 131.53 Cr | 0.00 Cr | 0.00 Cr | 17.88 Cr | 218.9100 Cr |
| 2023-06-30 | 435.05 Cr | 1,101.19 Cr | 350.30 Cr | 750.8900 Cr | 12.00 Cr | -423.05 Cr | 134.94 Cr | 173.27 Cr | 54.82 Cr | 0.00 Cr | -12.64 Cr | 303.9000 Cr |
| 2022-06-30 | 319.40 Cr | 893.72 Cr | 277.23 Cr | 616.4900 Cr | 2.83 Cr | -316.57 Cr | 115.21 Cr | 149.62 Cr | 0.56 Cr | 0.00 Cr | -3.83 Cr | 235.8300 Cr |
| 2021-06-30 | 464.05 Cr | 986.16 Cr | 282.45 Cr | 703.7100 Cr | 7.61 Cr | -456.44 Cr | 118.37 Cr | 140.13 Cr | 97.22 Cr | 0.00 Cr | -2.66 Cr | 238.9700 Cr |
| 2020-06-30 | 639.09 Cr | 1,176.38 Cr | 270.04 Cr | 906.3400 Cr | 0.00 Cr | -639.09 Cr | 136.00 Cr | 119.42 Cr | 1.10 Cr | 0.00 Cr | 3.37 Cr | 227.3400 Cr |
Annual Financials Cash Flow Statement
| Date | Operating Cash | Investing Cash | Financing Cash | Free Cash | Cash Change | Cash at End | CapEx | Income | Debt Repay | Dividends | Inventory |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2024-06-30 | 228.2800 Cr | -6.8700 Cr | -418.1100 Cr | 206.5600 Cr | -196.6900 Cr | 238.7300 Cr | -21.7300 Cr | 200.9800 Cr | 0.0000 Cr | -414.9900 Cr | 23.1300 Cr |
| 2023-06-30 | 236.0000 Cr | -21.5000 Cr | -98.4700 Cr | 193.5200 Cr | 116.0200 Cr | 435.4200 Cr | -42.4800 Cr | 314.2000 Cr | 0.0000 Cr | -93.7900 Cr | -32.3900 Cr |
| 2022-06-30 | 169.5200 Cr | -25.5400 Cr | -288.6300 Cr | 131.6000 Cr | -144.6500 Cr | 319.4000 Cr | -37.9200 Cr | 253.3700 Cr | 0.0000 Cr | -283.8500 Cr | -2.0200 Cr |
| 2021-06-30 | 247.2600 Cr | -32.2700 Cr | -386.6300 Cr | 194.6800 Cr | -171.6400 Cr | 464.0500 Cr | -52.5800 Cr | 233.2800 Cr | 0.0000 Cr | -381.7800 Cr | 15.2600 Cr |
| 2020-06-30 | 295.9300 Cr | 104.0800 Cr | -883.4100 Cr | 272.6600 Cr | -480.5200 Cr | 639.0900 Cr | -23.2700 Cr | 169.3875 Cr | 0.0000 Cr | -883.4100 Cr | -20.7500 Cr |
Quarterly Financial Income Report
| Date | Revenue | Co.Rev | GP | GPR | Operating Income | Net Income | EPS | EBITDA | NIR |
|---|---|---|---|---|---|---|---|---|---|
| 2024-12-31 | 309.77 Cr | 75.73 Cr | 234.04 Cr | 0.7555 | 117.88 Cr | 90.90 Cr | 54.76 | 127.39 Cr | 0.2934 |
| 2024-09-30 | 313.41 Cr | 140.04 Cr | 173.37 Cr | 0.5532 | 108.27 Cr | 82.33 Cr | 49.60 | 117.32 Cr | 0.2627 |
| 2024-06-30 | 283.88 Cr | 134.96 Cr | 148.92 Cr | 0.5246 | 41.09 Cr | 16.78 Cr | 10.11 | 30.19 Cr | 0.0591 |
| 2024-03-31 | 252.48 Cr | 126.57 Cr | 125.91 Cr | 0.4987 | 63.19 Cr | 46.56 Cr | 28.05 | 70.03 Cr | 0.1844 |
| 2023-12-31 | 309.97 Cr | 154.74 Cr | 155.23 Cr | 0.5008 | 94.73 Cr | 72.07 Cr | 43.42 | 106.83 Cr | 0.2325 |
Quarterly Financials Balance Sheet
| Date | Cash & Equiv. | Short-Term Inv. | Cash & Short-Term | Net Receivables | Inventory | Total Curr. Assets | PP&E (Net) | Total Assets | Total Liabilities |
|---|---|---|---|---|---|---|---|---|---|
| 2024-12-31 | 266.43 Cr | 25.83 Cr | 292.26 Cr | 0.00 Cr | 118.78 Cr | 612.49 Cr | 125.27 Cr | 870.15 Cr | 259.69 Cr |
| 2024-06-30 | 244.36 Cr | 0.00 Cr | 244.36 Cr | 85.33 Cr | 109.11 Cr | 524.22 Cr | 131.53 Cr | 794.36 Cr | 256.12 Cr |
| 2024-03-31 | -425.56 Cr | 851.12 Cr | 425.56 Cr | 0.00 Cr | 0.00 Cr | 425.56 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2023-12-31 | 425.56 Cr | 12.94 Cr | 425.56 Cr | 135.76 Cr | 129.05 Cr | 771.25 Cr | 168.14 Cr | 1,077.05 Cr | 271.17 Cr |
| 2023-09-30 | -435.05 Cr | 870.10 Cr | 435.05 Cr | 0.00 Cr | 0.00 Cr | 435.05 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
Quarterly Financials Cash Flow Statement
| Date | Net Income | Operating Cash Flow | Investing Cash Flow | Financing Cash Flow | Net Cash Change | Cash at End | Cash at Beginning | CapEx | Free Cash Flow |
|---|---|---|---|---|---|---|---|---|---|
| 2024-06-30 | 16.78 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2024-03-31 | 46.56 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2023-12-31 | 72.07 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2023-09-30 | 65.57 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2023-06-30 | 29.82 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
Splits History
| Date | Label | Split Ratio |
|---|---|---|
| No split history data available. | ||
Similar Stocks: Drug Manufacturers - Specialty & Generic
| Company Name | Symbol | Price | Market Cap | Volume |
|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | SUNPHARMA | ₹1,744.90 | ₹4,186,497,390,360.00 | ₹1,539,404.00 |
| Divi's Laboratories Limited | DIVISLAB | ₹5,891.50 | ₹1,564,008,080,155.00 | ₹717,304.00 |
| Torrent Pharmaceuticals Limited | TORNTPHARM | ₹3,254.60 | ₹1,101,504,496,478.00 | ₹168,941.00 |
| Mankind Pharma Limited | MANKIND | ₹2,588.40 | ₹1,067,918,241,168.00 | ₹342,053.00 |
| Dr. Reddy's Laboratories Limited | DRREDDY | ₹1,177.40 | ₹980,907,622,968.00 | ₹1,938,682.00 |
| Lupin Limited | LUPIN | ₹2,009.20 | ₹917,330,458,276.00 | ₹966,589.00 |
| Zydus Lifesciences Limited | ZYDUSLIFE | ₹845.35 | ₹850,616,530,500.00 | ₹1,860,605.00 |
| Aurobindo Pharma Limited | AUROPHARMA | ₹1,201.20 | ₹697,658,929,968.00 | ₹653,310.00 |
| Alkem Laboratories Limited | ALKEM | ₹5,000.40 | ₹597,872,826,000.00 | ₹97,948.00 |
| Glenmark Pharmaceuticals Limited | GLENMARK | ₹1,368.80 | ₹386,259,126,032.00 | ₹2,163,260.00 |
| Ipca Laboratories Limited | IPCALAB | ₹1,423.80 | ₹361,224,068,436.00 | ₹163,712.00 |
| Laurus Labs Limited | LAURUSLABS | ₹640.35 | ₹345,310,338,375.00 | ₹1,671,228.00 |
| Ajanta Pharma Limited | AJANTPHARM | ₹2,679.20 | ₹334,664,498,320.00 | ₹44,703.00 |
| Suven Pharmaceuticals Limited | SUVENPHAR | ₹1,202.20 | ₹306,037,994,912.00 | ₹330,131.00 |
| J. B. Chemicals & Pharmaceuticals Limited | JBCHEPHARM | ₹1,658.70 | ₹258,221,804,814.00 | ₹100,079.00 |
| Piramal Enterprises Limited | PEL | ₹1,039.85 | ₹234,462,986,345.00 | ₹552,041.00 |
| Wockhardt Limited | WOCKPHARMA | ₹1,401.40 | ₹227,698,028,558.00 | ₹264,593.00 |
| AstraZeneca Pharma India Limited | ASTRAZEN | ₹8,727.50 | ₹218,187,500,000.00 | ₹13,476.00 |
| Eris Lifesciences Limited | ERIS | ₹1,382.90 | ₹188,299,218,053.00 | ₹81,150.00 |
| Neuland Laboratories Limited | NEULANDLAB | ₹13,136.00 | ₹168,533,566,400.00 | ₹53,273.00 |
| Alembic Pharmaceuticals Limited | APLLTD | ₹849.65 | ₹167,009,863,405.00 | ₹223,768.00 |
| NATCO Pharma Limited | NATCOPHARM | ₹829.80 | ₹148,625,361,828.00 | ₹383,129.00 |
| Jubilant Pharmova Limited | JUBLPHARMA | ₹915.95 | ₹145,893,560,183.00 | ₹228,298.00 |
| Caplin Point Laboratories Limited | CAPLIPOINT | ₹1,906.70 | ₹144,931,500,763.00 | ₹146,966.00 |
| Glenmark Life Sciences Limited | GLS | ₹1,086.00 | ₹133,070,838,000.00 | ₹130,938.00 |
| Granules India Limited | GRANULES | ₹480.20 | ₹116,469,494,344.00 | ₹1,207,487.00 |
| Procter & Gamble Health Limited | PGHL | ₹5,223.50 | ₹86,706,866,654.00 | ₹3,571.00 |
| FDC Limited | FDC | ₹430.60 | ₹70,106,024,754.00 | ₹67,489.00 |
| Aarti Pharmalabs Limited | AARTIPHARM | ₹712.85 | ₹64,608,888,867.00 | ₹374,808.00 |
| Shilpa Medicare Limited | SHILPAMED | ₹658.10 | ₹64,356,197,871.00 | ₹163,074.00 |
| Strides Pharma Science Limited | STAR | ₹640.75 | ₹59,053,256,433.00 | ₹243,236.00 |
| Innova Captab Limited | INNOVACAP | ₹915.85 | ₹52,409,452,141.00 | ₹37,786.00 |
| Hikal Limited | HIKAL | ₹423.80 | ₹52,254,857,850.00 | ₹371,223.00 |
| Sun Pharma Advanced Research Company Limited | SPARC | ₹152.84 | ₹49,599,942,480.00 | ₹505,473.00 |
| Unichem Laboratories Limited | UNICHEMLAB | ₹633.90 | ₹44,630,236,620.00 | ₹75,809.00 |
| Orchid Pharma Limited | ORCHPHARMA | ₹799.75 | ₹40,562,604,224.00 | ₹101,985.00 |
| Sequent Scientific Limited | SEQUENT | ₹148.17 | ₹37,087,247,340.00 | ₹527,793.00 |
| RPG Life Sciences Limited | RPGLIFE | ₹2,179.20 | ₹36,041,821,488.00 | ₹10,217.00 |
| Gufic Biosciences Limited | GUFICBIO | ₹349.90 | ₹35,087,098,650.00 | ₹40,163.00 |
| Aarti Drugs Limited | AARTIDRUGS | ₹361.65 | ₹33,007,795,500.00 | ₹101,872.00 |
| Morepen Laboratories Limited | MOREPENLAB | ₹53.91 | ₹29,540,183,967.00 | ₹4,747,370.00 |
| Suven Life Sciences Limited | SUVEN | ₹127.13 | ₹27,723,712,024.00 | ₹173,057.00 |
| Alembic Limited | ALEMBICLTD | ₹105.35 | ₹27,051,965,791.00 | ₹436,085.00 |
| Solara Active Pharma Sciences Limited | SOLARA | ₹520.70 | ₹25,021,207,514.00 | ₹37,558.00 |
Key Executives
Company Secretary & Compliance Officer
Ms. Zeal Rupani
Gender: female
Year Born:
Chief Financial Officer, Finance Head & Executive Director
Mr. Lokesh Chandak
Gender: male
Year Born: 1987
MD & Executive Director
Mr. Milind Vasant Thatte M.B.A.
Gender: male
Year Born: 1969
Assistant Company Secretary
Ms. Prachi Vichare
Gender: female
Year Born:
FAQs about Procter & Gamble Health Limited
Who is the CEO of the company?
The CEO is Mr. Milind Vasant Thatte M.B.A..
What is the current market price of the stock?
The current price is ₹5,223.50.
What is the 52-week price range?
The range is ₹4636.55-5850.
What is the market capitalization of the company?
The market capitalization is ₹8,670.69 crores.
What is the dividend yield?
The dividend yield is 2.68%.
What is the Price-to-Earnings (P/E) ratio?
The P/E ratio is 36.65.
Which sector does the company belong to?
The company operates in the Healthcare sector.
What does the company do?
Overview of Procter & Gamble Health Limited (ISIN: INE199A01012) is a leading Drug Manufacturers - Specialty & Generic in India. With a market capitalization of ₹8,670.69 crores and an average daily volume of 8,963 shares, it operates in the Drug Manufacturers - Specialty & Generic. The company last declared a dividend of ₹160.